Abstract
Fifteen patients whose diastolic blood pressure (BP) was between 90-114 mmHg despite at least 2 weeks of therapy with once daily 25 mg hydrochlorothiazide (HCT) were randomized in a double-blind fashion to receive a single dose of either placebo or one of 2 doses of Remikiren (RMK) (200 or 400 mg) in addition to HCT. BP, HR, GFR, RPF, PRA, and IRR were measured 2 days before and on the randomization day. PRA reduced and IRR increased in a dose-dependent manner after both doses of RMK. BP decreased dose dependently mainly at the 6th hour postdose; HR did not change. While the mean GFR and RPF remained stable in the 3 groups, one patient in each RMK group exhibited a marked increase in RPF. These results indicate that both single doses of RMK, given in addition to diuretic therapy, are well tolerated. Moreover, despite pre-activation of the RAS, no large BP decreases nor any changes in kidney function could be demonstrated.
| Original language | Italian |
|---|---|
| Pages (from-to) | 43-51 |
| Number of pages | 9 |
| Journal | Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia |
| Volume | 12 |
| Issue number | 1 |
| Publication status | Published - 1995 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
L'INIBITORE DELLA RENINA REMIKIRENE (RO 42-5892), IN PAZIENTI IPERTESI IN TRATTAMENTO DIURETICO CRONICO : PROFILO ENDOCRINO ED EFFETTI EMODINAMICI SISTEMICI E RENALI. / Villa, G.; Picardi, L.; Kobrin, I.; Piatti, M.; Saponaro, R.; Salvadeo, A.
In: Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, Vol. 12, No. 1, 1995, p. 43-51.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - L'INIBITORE DELLA RENINA REMIKIRENE (RO 42-5892), IN PAZIENTI IPERTESI IN TRATTAMENTO DIURETICO CRONICO
T2 - PROFILO ENDOCRINO ED EFFETTI EMODINAMICI SISTEMICI E RENALI
AU - Villa, G.
AU - Picardi, L.
AU - Kobrin, I.
AU - Piatti, M.
AU - Saponaro, R.
AU - Salvadeo, A.
PY - 1995
Y1 - 1995
N2 - Fifteen patients whose diastolic blood pressure (BP) was between 90-114 mmHg despite at least 2 weeks of therapy with once daily 25 mg hydrochlorothiazide (HCT) were randomized in a double-blind fashion to receive a single dose of either placebo or one of 2 doses of Remikiren (RMK) (200 or 400 mg) in addition to HCT. BP, HR, GFR, RPF, PRA, and IRR were measured 2 days before and on the randomization day. PRA reduced and IRR increased in a dose-dependent manner after both doses of RMK. BP decreased dose dependently mainly at the 6th hour postdose; HR did not change. While the mean GFR and RPF remained stable in the 3 groups, one patient in each RMK group exhibited a marked increase in RPF. These results indicate that both single doses of RMK, given in addition to diuretic therapy, are well tolerated. Moreover, despite pre-activation of the RAS, no large BP decreases nor any changes in kidney function could be demonstrated.
AB - Fifteen patients whose diastolic blood pressure (BP) was between 90-114 mmHg despite at least 2 weeks of therapy with once daily 25 mg hydrochlorothiazide (HCT) were randomized in a double-blind fashion to receive a single dose of either placebo or one of 2 doses of Remikiren (RMK) (200 or 400 mg) in addition to HCT. BP, HR, GFR, RPF, PRA, and IRR were measured 2 days before and on the randomization day. PRA reduced and IRR increased in a dose-dependent manner after both doses of RMK. BP decreased dose dependently mainly at the 6th hour postdose; HR did not change. While the mean GFR and RPF remained stable in the 3 groups, one patient in each RMK group exhibited a marked increase in RPF. These results indicate that both single doses of RMK, given in addition to diuretic therapy, are well tolerated. Moreover, despite pre-activation of the RAS, no large BP decreases nor any changes in kidney function could be demonstrated.
KW - hypertension
KW - Remikiren
KW - renal hemodynamics
KW - renin-inhibitor
UR - http://www.scopus.com/inward/record.url?scp=0028847901&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028847901&partnerID=8YFLogxK
M3 - Articolo
VL - 12
SP - 43
EP - 51
JO - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
JF - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
SN - 0393-5590
IS - 1
ER -